Rhizen is Swiss HQ biotech focused on discovery and development of innovative, small molecule drugs for the treatment of cancer & inflammatory diseases.
We have demonstrated our leadership of the PI3K space through our discovery of Umbralisib & Tenalisib - class leading PI3K isoform-specific inhibitors that are poised to transform the NHL & CLL space.
We have a deep pipeline of novel differentiated assets across various stages of development.
Company Details
- Address
- Steinentorstrasse 23, Basel,4051,switzerland
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- https://www.rhizen.com/
- HQ
- Basel
Rhizen Pharmaceuticals Ag Questions
Rhizen Pharmaceuticals Ag's website is https://www.rhizen.com/
Rhizen Pharmaceuticals Ag's LinkedIn profile is https://ch.linkedin.com/company/rhizen-pharmaceuticals-ag
Rhizen Pharmaceuticals Ag's industry is
Research Services
Rhizen Pharmaceuticals Ag's top competitors are
Provectis Healthcare Ag,
Valerius Biopharma Ag,
Aum Biosciences,
Vrise Therapeutics, Inc.,
Debiopharm,
Stratpharma,
Metys Pharmaceuticals,
Novaremed Ag,
Med Indite Communications Pvt Ltd,
Cureleads.
Rhizen Pharmaceuticals Ag's categories are Research Services
